^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Anaplastic Thyroid Carcinoma…Systemic Therapy Regimens for Metastatic Disease...Preferred Regimens...pralsetinib...RET-fusion positive
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).